Overview

The Smith Alzheimer's Center at SIU Medicine offers wrap-around care and support for families.

Alzheimer’s disease is a brain disorder that slowly destroys memory and thinking skills, and, eventually, the ability to carry out the simplest tasks. In most people with Alzheimer’s, symptoms first appear later in life. Around 7 million Americans, most of them age 65 or older, have dementia caused by Alzheimer’s.

Clinicians use several methods and tools to help determine whether a person who is having memory problems has Alzheimer’s disease. To diagnose Alzheimer’s, doctors may: 

  • Ask the person and a family member or friend questions about overall health, use of prescription and over-the-counter medicines, diet, past medical problems, ability to carry out daily activities, and changes in behavior and personality.
  • Conduct tests of memory, problem solving, attention, counting, and language.
  • Carry out standard medical tests, such as blood and urine tests, to identify other possible causes of the problem.
  • Perform brain scans, such as computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET), to support an Alzheimer’s diagnosis or to rule out other possible causes for symptoms.

These tests may be repeated to give clinicians information about how the person’s memory and other cognitive functions are changing over time.

Common symptoms

Memory problems are typically one of the first signs of cognitive impairment related to Alzheimer’s. Some people with memory problems have a condition called mild cognitive impairment (MCI). With MCI, people have more memory problems than normal for their age, but their symptoms do not interfere with their everyday lives. Movement difficulties and problems with the sense of smell have also been linked to MCI. Older people with MCI are at greater risk for developing Alzheimer’s, but not all of them do so. Some may even revert to normal cognition.

Treatment options

If the diagnosis is Alzheimer’s, beginning treatment as early as possible in the disease process could help preserve daily functioning for a while. An early diagnosis also helps families plan for the future. 

The Smith Alzheimer's Center offers Beyond the Medical Center programs which center on art therapy, music therapy, movement and more for those with Alzheimer's and related dementias. These evidence-based programs are provided at no cost to families and focus on improving the quality of life for both people with Alzheimer's and their caregivers.

 

Care team

Profiles

Cindy Womack, DNP, FNP-BC, CNRN

Certified Nurse Practitioner Neurology
751 N. Rutledge St. Suite 3100 Springfield, IL 62702
Profiles

Mehul Trivedi, PhD

Clinical Psychologist Psychiatry
319 E Madison St 3rd Floor Springfield, IL 62702
Profiles

Lauri Lopp, MD

Physician Family Medicine
520 N. 4th St. Springfield, IL 62702
Profiles

Jennifer Arnold, MD

Neurologist Neurology
751 N. Rutledge St. Suite 3100 Springfield, IL 62702
Profiles

Andrea Perkins, DNP, FNP-BC

Certified Nurse Practitioner Neurology
751 N. Rutledge St. Suite 3100 Springfield, IL 62702
Profiles

Dale Korinek, Psy.D

Clinical Neuropsychologist Psychiatry
319 E Madison St 3rd Floor Springfield, IL 62702
Profiles

Charlene Young, FNP-BC

Certified Nurse Practitioner Neurology
751 N. Rutledge St. Suite 3100 Springfield, IL 62702
Profiles

Priyanka Bhandari, MD

Physician Family Medicine
520 N. 4th St. Springfield, IL 62702

 

Image
SIU Medicine Researcher in Lab

 

Care facilities

Locations
Locations
Locations

 

Clinical trials

Trial
Neurology

A 6-month (stage 1) & 18-month (stage 2) prospective, randomized, placebo-controlled, doubleblind dual clinical trial investigating efficacy and safety of buntanetap in treating participants with early Alzheimer’s disease

Active recruiting
In this study, the safety and efficacy of buntanetap will be assessed in a diverse population of early AD participants via a randomized, double-blind, placebo-controlled, multicenter Phase 3 trial.
Trial
Neurology

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild to Moderate Alzheimer’s Disease (MINDSET 2)

Active recruiting
The purpose of this research is to learn if the experimental study drug KarXT + KarX-EC works to treat thinking and memory problems as well as improve overall function in people with Alzheimer’s disease (AD).
Trial
Neurology

ADCS Benfo: A Seamless Phase 2A-Phase 2B Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients with Early Alzheimer’s Disease (BenfoTeam)

Active recruiting
The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine, to determine whether it delays or slows the progression of the symptoms of early Alzheimer’s disease.
Trial
Neurology

Athira: A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Evaluate Safety and Efficacy of ATH-1017 Treatment in Alzheimer’s Dementia Patients

Active recruiting

ATH-1017-AD-201: The purpose of this study is to compare the effects, good or bad, of ATH-1017 on patients with mild to moderate Alzheimer's Disease.